TransMedics Group, Inc. logo
TransMedics Group, Inc. (TMDX)
Compare

TransMedics Group, Inc. (TMDX) Current vs Average EV/EBIT Ratio

EV/EBIT Ratio

How TransMedics Group, Inc. (TMDX)'s current ev/ebit ratio of 34.45x compares to its TTM/3Y/5Y/10Y/15Y/20Y averages as of Saturday, June 20, 2026.

Current vs Average EV/EBIT Ratio Chart

TMDX EV/EBIT Ratio vs Average

CURRENT VS TTM AVG

-39.51%

CURRENT VS 3Y AVG

-49.74%

CURRENT VS 5Y AVG

-49.74%

CURRENT VS 10Y AVG

-49.74%

CURRENT VS 15Y AVG

-49.74%

CURRENT VS 20Y AVG

-49.74%

About TransMedics Group, Inc.

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

Andover, MA
728 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Waleed H. Hassanein